134
Participants
Start Date
November 9, 2017
Primary Completion Date
January 4, 2021
Study Completion Date
January 4, 2021
Meropenem 6g IV over 6 hours
Meropenem 6g intravenously over 6 hours once daily on days 1-14.
Ertapenem 1g IM
Ertapenem 1g intramuscularly once daily on days 1-14.
Meropenem 3g IV
Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
Ertapenem 1g IV
Ertapenem 1g intravenously once daily on days 1-14.
Amoxicillin/CA twice daily
Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
Rifampicin 35 mg/kg
Rifampicin 35 mg/kg once daily on days 1-14.
Meropenem 6g IV over 60 minutes
Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
Rifafour e-275
Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
Meropenem 4g IV
Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
Amoxicillin/CA once daily
Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
TASK Clinical Research Centre, Cape Town
TASK Applied Science
OTHER